<DOC>
	<DOCNO>NCT01363934</DOCNO>
	<brief_summary>This Dose-Block Randomized , Double-blind Placebo control , Open-label Active control , Dose-escalation Study investigate safety , tolerability , Pharmacokinetics/Pharmacodynamics GC1113 Single Intravenous/Subcutaneous Administration Healthy Male Subjects .</brief_summary>
	<brief_title>To Evaluate Safety , Tolerability , Pharmacokinetics/Pharmacodynamics Erythropoietin</brief_title>
	<detailed_description />
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Written inform consent Adult male subject 20 55 year age 60kg ≤ weight ≤ 90kg , 19 ≤ BMI ≤ 27 12 g/dL ≤ Hemoglobin ≤ 16 g/dL within 28 day prior investigational product ( IP ) injection WBC ≥ 3.0Ⅹ10^9/L , platelet ≥ 140Ⅹ10^9/L within 28 day prior IP injection Allergic IP ingredient History uncontrolled liver , kidney , respiratory , endocrine , neurology , immunology , hematology , mental symptom , circulatory malignancy disease Prior exposure EPO , darbepoetin , EPO , immunoglobulin , IV iron supplementation History hypersensitivity reaction EPO , darbepoetin , excipient IP hyperergia iron supplementation Epilepsy within 6 month prior IP injection Positivity HIV antibody , HBsAg , HCV antibody test Spleen length &gt; 16㎝</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Erythropoietin</keyword>
	<keyword>EPO-hFC</keyword>
</DOC>